Litigation Details for AstraZeneca AB v. Alembic Pharmaceuticals Limited (D. Del. 2020)

AstraZeneca AB v. Alembic Pharmaceuticals Limited (D. Del. 2020)

Docket	1:20-cv-00202	Date Filed	2020-02-11
Court	District Court, D. Delaware	Date Terminated	2022-04-25
Cause	35:1 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	10,183,020
Link to Docket	External link to docket

Details for AstraZeneca AB v. Alembic Pharmaceuticals Limited (D. Del. 2020)

Date Filed	Document No.	Description	Snippet	Link To Document
2020-02-11				External link to document
2020-02-11	228	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,183,020. (Attachments: # 1…2020 25 April 2022 1:20-cv-00202 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2020-02-11	4	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,183,020. (lak) (Entered: 02…2020 25 April 2022 1:20-cv-00202 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Litigation summary and analysis for: AstraZeneca AB v. Alembic Pharmaceuticals Limited (D. Del. 2020)

Last updated: July 21, 2026

AstraZeneca AB v. Alembic Pharmaceuticals Limited (1:20-cv-00202): Litigation Summary, Claims at Issue, and Commercial Impact

AstraZeneca AB’s federal case against Alembic Pharmaceuticals Limited (case no. 1:20-cv-00202) is a US Hatch-Waxman patent infringement dispute tied to an ANDA and Orange Book-listed intellectual property for an AstraZeneca product. The record supports that AstraZeneca sought relief for Alembic’s generic entry plans, including infringement of one or more Orange Book patents. The case timeline, procedural posture, and any settlement or final merits resolution determine whether Alembic’s launch can proceed before patent expiration and whether subsequent Paragraph IV filings face injunction risk.

---

What court and case details define AstraZeneca AB v. Alembic Pharmaceuticals Limited 1:20-cv-00202?

Forum and docket

• Court: U.S. District Court for the District of Delaware (commonly docketed as “D. Del.” for this numbering pattern)
• Case number: 1:20-cv-00202
• Parties: AstraZeneca AB (plaintiff) vs. Alembic Pharmaceuticals Limited (defendant)
• Filing year: 2020 (as reflected by docket number)

What this typically signals in Hatch-Waxman In ANDA litigation in Delaware under this case structure, the plaintiff’s complaint typically alleges that the ANDA product would infringe one or more patents listed for the reference listed drug (RLD) in the FDA’s Orange Book due to Alembic’s certification (usually a Paragraph IV certification) to one or more Orange Book patents.

Core dispute mechanics

• Alembic files an ANDA referencing an AstraZeneca RLD.
• Alembic includes Paragraph IV certifications challenging one or more listed patents.
• AstraZeneca sues within the statutory window under 35 U.S.C. § 271(e)(2).

Litigation artifacts used to map infringement scope For an infringement analysis that is decision-grade, the most probative documents are:

• the Complaint (asserted patents and infringement theories),
• Alembic’s Answer (noninfringement/invalidity defenses),
• any Markman order (claim construction),
• the claim charts or infringement contentions,
• dispositive motions (summary judgment on noninfringement/invalidity),
• and any stipulations or dismissals tied to a settlement.

---

Which patents and Orange Book listings are likely at issue in 1:20-cv-00202?

Featured-snippet answer (litigation mapping) The operative patents in 1:20-cv-00202 are the Orange Book-listed patents that AstraZeneca alleged Alembic infringed based on Alembic’s ANDA Paragraph IV filing.

How courts identify “which patents” for business use Litigation planners typically triangulate the asserted patent set from:

• the captioned patent list in the complaint,
• the “Patent-In-Suit” section of infringement contentions,
• and the schedule of asserted claims used for Markman.

Patent categories most frequently asserted in AstraZeneca ANDA actions For AstraZeneca RLDs, the asserted estate often includes some mix of:

• Composition of matter patents (core active ingredient or drug substance);
• Formulation patents (tablet/capsule composition, coating, polymorph, solvate/hydrate);
• Method-of-use patents (dosage regimens, patient subpopulations, therapeutic methods);
• Manufacturing or process patents (less common but present depending on the product).

Implication for generic launch The number of patents asserted and their category matters:

• Composition-of-matter and formulation patents can block commercial entry until expiration or a narrow design-around.
• Method-of-use patents can limit claims but may allow “carve-out” labeling or amended indications if the asserted use is not covered.

---

What is the procedural posture of AstraZeneca AB v. Alembic Pharmaceuticals Limited 1:20-cv-00202?

Featured-snippet answer (how to read posture fast) The case posture in Hatch-Waxman disputes typically progresses through:

1. complaint and answer,
2. Markman claim construction,
3. infringement and invalidity phases (often with summary judgment),
4. trial if not resolved by motion or settlement,
5. entry timing control via settlement and/or court rulings.

Business-critical posture drivers

• Dismissal without prejudice or narrowing of asserted claims: reduces risk to Alembic.
• Permanent injunction: delays launch until patent expiry or appellate resolution.
• No infringement finding: accelerates generic entry timeline.
• Invalidity ruling: clears the path to launch, often with immediate FDA implications.
• Settlement: creates a de facto exclusivity window if it includes delayed launch and compensation provisions.

Why posture drives revenue exposure AstraZeneca’s commercial exposure depends on whether Alembic can market before:

• patent expiration dates, or
• exclusivity expiry dates (including potential pediatric exclusivity, if applicable),
• or an at-risk launch window following final judgment.

---

What claim constructions and infringement theories typically decide Hatch-Waxman cases like 1:20-cv-00202?

Featured-snippet answer In Hatch-Waxman patent disputes, claim construction and infringement contentions usually determine whether Alembic’s ANDA product “reads” on specific claim elements, especially for formulation and method claims.

Common infringement fault lines

• Molecule identity for composition claims (salt/polymorph or stereochemistry coverage)
• Drug product characteristics for formulation claims (particle size, excipient definitions, coatings)
• Dosage regimen boundaries for method claims (exact dose ranges, frequency, duration)
• Labeling-driven “use” claims for method-of-use patents (the proposed ANDA labeling matters)

Noninfringement defenses frequently used

• Alembic product does not contain the required physical form or characteristic.
• Claim elements are missing from the ANDA product composition.
• The claimed method does not match Alembic labeling.

Invalidity defenses frequently used

• Lack of novelty or obviousness over prior art.
• Indefiniteness or insufficient written description.
• Enablement issues for complex formulation claims.

---

When does the AstraZeneca patent estate lose exclusivity versus when does Alembic launch become permitted?

Featured-snippet answer Launch permission is a function of (1) patent expiration and (2) court outcomes affecting injunctions, or (3) settlement terms permitting entry on a specified date.

Timelines that control entry Hatch-Waxman entry timing is often controlled by:

• statutory “30-month stay” triggered by a timely Paragraph IV suit,
• earlier or later lift depending on court schedules and decisions,
• and any settlement entry date that overrides at-risk launch expectations.

What must be known to compute dates precisely The exact asserted patents’ expiration and any exclusivity extensions would determine the “earliest launch” date. That requires the asserted patent numbers and their expiration data as listed in the Orange Book and patent term adjustments.

---

What settlement outcomes are typical, and how do they affect Paragraph IV risk for Alembic?

Featured-snippet answer If the parties settled, Alembic’s launch date usually becomes fixed by the agreement’s entry trigger and any “carve-out” conditions, with residual litigation risk centered on enforcement of settlement terms.

Common settlement structures in ANDA litigation

• Delayed launch until a stated date (often tied to patent expiry or a negotiated earlier date).
• At-launch stipulations on noninfringement or labeling.
• Payment terms that compensate for delay (subject to applicable antitrust oversight, though the litigation document controls enforceability).
• Dismissal with prejudice or covenants not to sue tied to the specific ANDA product configuration.

Paragraph IV risk implication Even after settlement, the generic risk profile often shifts:

• New entry risks exist for other unasserted patents (if any remain Orange Book listed).
• Enforcement risk increases if Alembic’s product or labeling deviates from agreed boundaries.

---

How strong is AstraZeneca’s patent estate in this case based on litigation focus?

Featured-snippet answer In Hatch-Waxman cases, AstraZeneca’s estate strength is reflected in the breadth of asserted patents, the number of independent claims surviving early motion practice, and whether the case resolves via consent judgment, dispositive motion, or settlement.

Indicators used by practitioners

• Number of patents asserted: more patents typically increases settlement leverage and blocking probability.
• Claim survival through Markman: narrow constructions often reduce infringement odds.
• Summary judgment posture: if the court denies key motions, infringement or validity may proceed to trial.
• Consent judgments: usually implies negotiated outcome anchored to an identified set of issues.

What “strong” means operationally For business stakeholders, “strong” means:

• there is an enforceable injunction threat,
• and/or there is a credible path to delayed entry through final resolution.

---

What generic entry risks exist for Alembic if AstraZeneca prevails or partially prevails?

Featured-snippet answer If AstraZeneca prevails on at least one asserted patent, Alembic faces an injunction risk preventing commercial launch until infringement is designed around or the patent expires.

Risk matrix

• If infringement is found and validity is upheld: Alembic’s launch is blocked.
• If invalidity is found: Alembic can launch on the invalidated patents, but may still be blocked by other listed patents not ruled on.
• If some patents are dropped/dismissed: remaining patents control.
• If the court construes claims narrowly: Alembic may design around without changing regulatory authorization.

---

What is the FDA regulatory status significance for 1:20-cv-00202 litigation?

Featured-snippet answer FDA exclusivity and Orange Book listings set the legal gating factors, while litigation outcomes determine whether Alembic’s ANDA can be approved and marketed before patent expiry.

Regulatory vectors that affect timing

• ANDA approval can be delayed by patent litigation outcomes even if FDA finds approval-ready quality and bioequivalence.
• FDA labeling may be adjusted to avoid method-of-use infringement, but that only works if the patent-in-suit is genuinely labeling-sensitive and the claim scope is consistent with the label carving.

---

How does Alembic’s ANDA posture compare with other challengers in similar AstraZeneca matters?

Featured-snippet answer AstraZeneca litigations against multiple generic filers often share:

• Paragraph IV triggers,
• similar asserted patent estates,
• and settlement-led entry dates that standardize the commercial outcome.

Market-level implication Even if this specific case resolves for or against Alembic, the broader competitive landscape depends on:

• how many other ANDA filers are waiting in the queue,
• whether other challengers settled earlier or later,
• and whether AstraZeneca continues asserting the remaining patents in separate suits.

---

Key Takeaways

• 1:20-cv-00202 is a US Hatch-Waxman patent infringement dispute arising from Alembic’s ANDA challenge(s) to AstraZeneca Orange Book-listed patents.
• The case’s commercial impact is governed by the asserted patent set, claim construction, and whether resolution came via final judgment or settlement.
• For launch-risk assessment, decision-grade analysis requires identifying the patents-in-suit and mapping them to expiration dates, exclusivity overlays, and any injunction or settlement entry triggers.

---

FAQs

1) What is a “Paragraph IV” filing and how does it connect to 1:20-cv-00202?

A Paragraph IV filing is a certification by the ANDA applicant that an Orange Book patent is invalid, unenforceable, or will not be infringed; it triggers infringement litigation and controls FDA approval and launch timing.

2) How does a 30-month stay affect AstraZeneca vs. Alembic ANDA cases?

A timely Paragraph IV suit typically triggers a statutory 30-month stay on certain FDA approval steps, subject to early resolution or specific timing events.

3) Can Alembic launch “at risk” while litigation is pending in AstraZeneca AB v. Alembic Pharmaceuticals Limited?

If no injunction or binding resolution blocks launch and if approval is otherwise permitted, “at risk” entry can occur depending on procedural status and court orders.

4) What role do method-of-use claims play in ANDA litigation like this?

Method-of-use patents can be managed via labeling carve-outs if the proposed ANDA labeling does not induce infringement of the claimed method.

5) If AstraZeneca settles, what typically determines when Alembic can enter the market?

Settlement terms usually set a specific entry date and may require agreed product and labeling conditions tied to the ANDA version in dispute.

---

References

(No sources were provided in the prompt, and no verified docket or patent-assertion documents are included above. Per operating constraints, no citations can be generated without a citable source base.)